Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover access study for dabrafenib and/or trametinib
NL-OMON60137Phase 4Recruiting
- Sponsor
- Novartis
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dabrafenib + trametinib and trametinib, sponsored by Novartis. Started Sep 2021; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
Beyond the preview
Go deeper on NL-OMON60137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60137.